Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations -- Lanas et al. 55 (12): 1731 Data Supplement

Gut 2006;55:1731-1738
© by BMJ Publishing Group Ltd & British Society of Gastroenterology

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
A Lanas, L A García-Rodríguez, M T Arroyo, F Gomollón, F Feu, A González-Pérez, E Zapata, G Bástida, L Rodrigo, S Santolaria, M Güell, C M de Argila, E Quintero, F Borda, J M Piqué, and on behalf of the Investigators of the Asociación Española de Gastroenterología (AEG)

Competing interests: AL has received fees for speaking, research or travel support from AstraZeneca, Merck Sharp & Dhome, Pfizer, Almirall Prodesfarma and TAP. LAG-R has received fees for speaking from Merck Sharp & Dhome, Pfizer and AstraZeneca, and research grants from Pfizer and AstraZeneca. FG, EQ, LR and JMP have received fees for speaking and research grants or travel support from AstraZeneca, Merck, Pfizer and Almirall Prodesfarma. The other authors have not reported conflict of interest.